Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies. Approximately 70 percent of patients who received Lemtrada in two courses of treatment over two years did not need to receive further treatment with the drug during the two-year extension study, Genzyme said in a statement on Thursday. Genzyme will detail the results of its latest studies before the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS).

Read the full article...

(From Yahoo Diseases)